CELSUS™

Early detection of oncology.

Russian market

- Total Addressable Market for 1 year

  $125 mln

- Serviceable Available Market for 1 year

  $51 mln

- Serviceable & Obtainable Market for 1 year

  $36 mln

Number of public health facilities for 2018	6228
Private specialized medical centers and medical organizations of large corporations for 2018	1568
Average cost per mammography study	$1,2
Average cost per fluorography study	$0,7
Private Practitioners for 2018	25613

CELSUS™

Foreign market volume in the case of Germany

- Total Addressable Market for 1 year

  $50 mln

- Serviceable Available Market for 1 year

  $17,5 mln

- Serviceable & Obtainable Market for 1 year

  12,6 mln

Number of public and private specialized medical institutions for 2019	More than 2000
Women's population	42 101 000 people
Women over 40 years old	23 998 000 people
Average cost per mammography study	$2 (minimal cost)

Achievements

- Winner of the first open battles of AI-based services for radiation diagnostics at the "Final Conference of Radiologists and Radiologists of Russia", 2019

- Winner of the "Цифровые вершины" (Digital Heights) award in the category "The best solution using artificial intelligence to improve efficiency", 2019

Team

Chernin Stanislav
CEO - experience in attracting investments and launching new projects since 2012, successful experience in developing and selling startup companies.

Kapninskiy Artem
CMO, CBDO - experience in launching new projects and project management since 2008, successful experience in overcoming the crisis and further selling existing service companies.

Nikitin Evgeny
CTO, CIO Data Science, Grade Master in University of Warwick, PhD candidate in New York University, Playrix analyst.

Staff on January 01, 2020 - 34 people:

Full-part team– 29 people
Part-time time – 5 people

CELSUS™

Problems in oncology

Untimely diagnosis of cancer diseases:

- In 2018, detection of malignant breast tumor at stage I amounted to only 26% of the total number of diagnoses
- In 2018, the mortality rate from breast cancer was 22295 people

- lack of qualified personnel
- «human factor»
- high costs of diagnostic procedures

Solution

CELSUS™ - a complex neural network.

The system of assistance in making medical decisions based on neural networks (artificial intelligence) by analyzing digital medical images, detecting pathological objects and interpreting the results according to international standards.

CELSUS™

Results

Reducing diagnostic costs

Minimizing the risks associated with the "human factor" in doctors' work

Compensation of understaffing or lack of stuff

Saving Lives

CELSUS™

Why now?

Evolution of new technologies and Data science;

Increasing computing powers;

Understanding of real approaches to the use of information technologies in medicine in conjunction with physicians;

Large free market

CELSUS™ - ready-made solution!

CELSUS™

Solution efficiency

Interpretation accuracy over 95% for Bi-Rads



Our strengths and assets

- ✓ The customer does not need to purchase expensive equipment and long training of employees to operate it
- ✓ Support for HL7/FHIR (international) protocols
- ✓ Integration with any medical and radiological information systems, medical image archives
- ✓ Interpretation of research results based on the algorithm of the doctor's actions (based on a set of factors), the choice of standard for the doctors' interpretations;
- ✓ Presence of a patent for invention in Russia
- ✓ International application was filed under PCT procedure
- ✓ Optimized algorithms and tools for Dataset's preparation and marking
- ✓ Availability of a system of quality control of markings by physicians – radiologists
- ✓ Registered trademark
- ✓ Pilot projects in 6 regions of the Russian Federation. **15 regional agreements**

Competitors

Russian federation

- Botkin. AI - small startup. There are no performance indicators of the solution in open access, hired team of developers, investments attracted, occupy less than 1% of the market.
- Третье мнение (Third Opinion) - startup. There are no indicators of the solution's performance in the open access, investments attracted, no patents for invention.

International competitors

- Lunit - Republic of Korea;
- Zebra Med – Israel;
- IBM Watson AI – USA;
- Google DeepMind AI – ISA;
- Kheiron Medical – UK;
- QuantX – USA.

Potential partners



Clients



Operating model



CELSUS™ Technology

Artem Kapninskiy

 +7 (909) 251 – 81 – 66

 a.kapninskiy@celsus.ai

 celsus.ai